$GCTKMay 26, 2026, 7:07 PMAI processed
Glucotrack to present implantable CGM at ADA; says IDE submitted to FDA
AI Summary
Glucotrack (GCTK) will present its fully implantable continuous blood glucose monitor at the ADA 2026 Scientific Sessions on June 6, highlighting direct-blood measurement, multi-year implant longevity and a no-wearable design. The company says it submitted an IDE to the FDA this month and published two peer-reviewed studies showing year-long enzyme stability and a 6.8% MARD over 240 days in an ovine model—supporting a move toward a U.S. clinical study, though the results are preclinical and the device remains investigational.
Positives
- Submitted Investigational Device Exemption (IDE) to FDA this month, a key step toward U.S. clinical trials
- Two peer-reviewed studies published showing year-long enzyme stability and 6.8% MARD over 240 days in an ovine model
- Scheduled presentation at ADA 2026 gives visibility to technology and engagement with the diabetes community
Negatives
- Key accuracy/longevity data reported are from an ovine (animal) model, not human clinical data
- IDE is pending—no FDA approval or human trial results yet
- Device remains investigational and limited to investigational use until regulatory clearance